-
公开(公告)号：US10028937B2
公开(公告)日：2018-07-24
申请号：US15434789
申请日：2017-02-16
Applicant: AbbVie Inc.
Inventor： Mary E. Bellizzi , David A. Betebenner , Jean-Christophe C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC: A61K38/00 , C07K16/00 , A61K31/4184 , A61K31/454 , A61K31/4439 , A61K31/422 , A61K31/4418 , A61K31/4545 , A61K31/695 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/438 , A61K31/435
CPC classification number: A61K31/454 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/435 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07F7/02 , Y02P20/582
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号：US20160355530A1
公开(公告)日：2016-12-08
申请号：US15240753
申请日：2016-08-18
Applicant: AbbVie Inc. , Abbott Products GmbH
Inventor： Clarence J. Maring , John K. Pratt , William A. Carroll , Dachun Liu , David A. Betebenner , Douglas K. Hutchinson , Michael D. Tufano , Todd W. Rockway , Uwe Schoen , Axel Pahl , Andreas Witte
IPC: C07F7/18 , A61K31/4178 , C07D417/14 , A61K31/427 , C07D413/14 , A61K31/5377 , C07D413/04 , A61K31/5395 , C07D471/04 , A61K31/437 , A61K31/506 , A61K31/695 , C07D405/04 , A61K31/422
CPC classification number: C07F7/1804 , A61K31/4178 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K31/5395 , A61K31/541 , A61K31/675 , A61K31/695 , A61K45/06 , B65D88/703 , C07D405/04 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07F9/65586 , F16K31/363 , Y10T137/86405 , Y10T137/86421
Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
Abstract translation: 本公开涉及：（a）其特别是抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。
-
公开(公告)号：US20150218194A1
公开(公告)日：2015-08-06
申请号：US14683910
申请日：2015-04-10
Applicant: AbbVie Inc.
Inventor： Mary E. Bellizzi , David A. Betebenner , Jean C. Califano , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC: C07F9/6558 , C07D405/14 , C07D403/14 , C07D401/14 , C07D207/09 , C07D491/113 , C07D413/14 , C07D471/04 , C07C201/06 , C07D207/08 , C07D207/16 , C07D417/14
CPC classification number: C07F9/65583 , C07C33/26 , C07C201/06 , C07C205/19 , C07D207/08 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D471/04 , C07D491/113 , C07K5/06
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Abstract translation: 描述了有效抑制丙型肝炎病毒（“HCV”）复制的化合物。 本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。
-
公开(公告)号：US20150111890A1
公开(公告)日：2015-04-23
申请号：US14395628
申请日：2013-04-19
Applicant: AbbVie Inc.
Inventor： Lisa A. Hasvold , Dachun Liu , Chang Hoon Park , John K. Pratt , George S. Sheppard , Le Wang
IPC: C07D409/12 , A61K31/4035 , C07D403/04 , A61K31/404 , C07D405/04 , A61K31/416 , C07D405/10 , A61K31/5377 , C07D401/12 , A61K31/4439 , A61K31/4709 , C07D403/12 , C07D209/44 , A61K31/4184
CPC classification number: C07D409/12 , A61K31/4035 , A61K31/404 , A61K31/416 , A61K31/4184 , A61K31/427 , A61K31/4439 , A61K31/4709 , A61K31/5377 , A61K45/06 , C07D209/44 , C07D209/48 , C07D401/10 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/10 , C07D405/12 , C07D409/10 , C07D417/12
Abstract: The present invention provides for compounds of formula (I) wherein A, Y, J, R1, R2, and R3 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof,that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
Abstract translation: 本发明提供式（I）化合物，其中A，Y，J，R 1，R 2和R 3具有说明书中定义的任何值及其药学上可接受的盐，其可用作治疗 疾病和病症，包括炎性疾病，糖尿病，肥胖症，癌症和艾滋病。 还提供了包含一种或多种式（I）化合物的药物组合物。
-
公开(公告)号：US09006387B2
公开(公告)日：2015-04-14
申请号：US14180886
申请日：2014-02-14
Applicant: AbbVie, Inc.
Inventor： Rolf Wagner , John K. Pratt , Dachun Liu , Michael D. Tufano , David A. DeGoey , Warren M. Kati , Charles W. Hutchins , Pamela L. Donner , John T. Randolph , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , Mark A. Matulenko , Ryan G. Keddy , Tammie K. Jinkerson , Todd W. Rockway , Clarence J. Maring , Douglas K. Hutchinson , Charles A. Flentge , David A. Betebenner , Kathy Sarris , Kevin R. Woller , Seble H. Wagaw , Jean C. Califano , Wenke Li , Daniel D. Caspi , Mary E. Bellizzi , Yi Gao , Allan C. Krueger
IPC: C07K16/00 , A61K38/00 , C07K5/06 , C07D401/14 , C07D403/14 , C07D417/14 , C07C33/26 , C07C205/19
CPC classification number: C07F9/65583 , C07C33/26 , C07C201/06 , C07C205/19 , C07D207/08 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D471/04 , C07D491/113 , C07K5/06
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
Patent Agency Ranking
公开(公告)号：US20150087618A1
公开(公告)日：2015-03-26
申请号：US14558318
申请日：2014-12-02
Applicant: AbbVie Inc.
Inventor： Mary E. Bellizzi , David A. Betebenner , Jean C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC: C07F7/02 , C07D405/14 , C07D403/14 , C07D401/14 , C07D413/14
CPC classification number: A61K31/454 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/435 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07F7/02 , Y02P20/582
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号：US20150056164A1
公开(公告)日：2015-02-26
申请号：US14260504
申请日：2014-04-24
Applicant: AbbVie Inc.
Inventor： David A. Betebenner , John K. Pratt , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Douglas K. Hutchinson , Warren M. Kati , Allan C. Krueger , Kenton L. Longenecker , Clarence J. Maring , John T. Randolph , Todd W. Rockway , Michael D. Tufano , Rolf Wagner , Dachun Liu
IPC: C07D409/10 , A61K31/513 , C07D213/64 , A61K31/4418 , C07C311/08 , A61K45/06 , C07D233/72 , A61K31/4166 , A61K31/27 , C07D263/24 , A61K31/421 , C07D239/54 , A61K31/18
CPC classification number: C07D409/10 , A61K31/18 , A61K31/27 , A61K31/402 , A61K31/4166 , A61K31/421 , A61K31/425 , A61K31/4418 , A61K31/503 , A61K31/513 , A61K45/06 , C07C311/08 , C07D207/27 , C07D213/64 , C07D233/32 , C07D233/72 , C07D239/10 , C07D239/54 , C07D263/22 , C07D263/24 , C07D275/02 , C07D403/10 , C07D405/10 , Y02P20/55
Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
Abstract translation: 本发明涉及：（a）特别是抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。
-
公开(公告)号：US20140235638A1
公开(公告)日：2014-08-21
申请号：US14230965
申请日：2014-03-31
Applicant: AbbVie Inc.
Inventor： Rolf Wagner , Warren M. Kati , Dachun Liu , Yaya Liu , Kenton L. Longenecker , Clarence J. Maring , John K. Pratt , Todd W. Rockway , Kent D. Stewart , Michael D. Tufano
IPC: C07D239/54 , C07D413/10 , C07D417/10 , A61K31/5377 , C07D401/10 , C07D405/10 , C07D409/10 , C07D417/14 , A61K31/513 , C07D403/10
CPC classification number: A61K31/513 , A61K31/5377 , C07D239/22 , C07D239/54 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , C07D417/14
Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
Abstract translation: 本发明涉及：（a）其特别是HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。
-
公开(公告)号：US20130303547A1
公开(公告)日：2013-11-14
申请号：US13944447
申请日：2013-07-17
Applicant: AbbVie Inc.
Inventor： Brian E. Green , David D. Anderson , Todd D. Bosse , Curt S. Cooper , Larry L. Klein , Allan C. Krueger , Daniel P. Larson , Dachun Liu , Keith F. McDaniel , Christopher E. Motter , John K. Pratt , Todd W. Rockway , Teresa A. Rosenberg , Ming C. Yeung , Hui-Ju Chen , Jason P. Shanley
IPC: C07D403/12 , C07D409/14 , C07D403/14 , C07D207/16 , C07D241/24
CPC classification number: C07D403/12 , C07D207/16 , C07D241/24 , C07D403/14 , C07D409/14 , C07K7/02
Abstract: This invention relates to: (a) compounds of formula I and salts thereof that, inter alia, are useful as hepatitis C virus (HCV) inhibitors; (b) intermediates useful for the preparation of such compounds and salts; (c) pharmaceutical compositions comprising such compounds and salts; and (d) methods of use of such compounds, salts, and compositions.
Abstract translation: 本发明涉及：（a）式I化合物及其盐，其特别可用作丙型肝炎病毒（HCV）抑制剂; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的药物组合物; 和（d）使用这些化合物，盐和组合物的方法。
-
公开(公告)号：US20250152600A1
公开(公告)日：2025-05-15
申请号：US18742823
申请日：2024-06-13
Applicant: AbbVie Inc.
Inventor： Le Wang , John K. Pratt , Keith F. McDaniel , Steven D. Fidanze , Lisa Hasvold , James H. Holms , Warren M. Kati , Dachun Liu , Robert A. Mantei , William J. McClellan , George S. Sheppard , Carol K. Wada , Yujia Dai
IPC: A61K31/541 , A61K31/437 , A61K31/5025 , A61K31/5377 , A61K45/06 , C07D471/04 , C07D487/04
Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
-
-
-
-
-
-
-
-
-
Search Results
36
records
(took 0.083 seconds)
